Brincidofovir is not a substrate for the human organic anion transporter 1: A mechanistic explanation for the lack of nephrotoxicity observed in clinical studies

Therapeutic Drug Monitoring

Volumn 38, Issue 6, 2016, Pages 777-786

  Tippin, Timothy K ^a   Morrison, Marion E ^a   Brundage, Thomas M ^a   Momméja Marin, Hervé ^a  

^a Chimerix   (United States)

Author keywords

Brincidofovir; Cidofovir; DsDNA virus; OAT1; Renal function

Indexed keywords

BRINCIDOFOVIR; CREATININE; FOSCARNET; GANCICLOVIR; NITROGEN; ORGANIC ANION TRANSPORTER 1; PROBENECID; TACROLIMUS; UREA; ANTIVIRUS AGENT; CYTOSINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; KIDNEY FAILURE; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHILD; DOG; DRUG EFFECTS; FEMALE; GLOMERULUS FILTRATION RATE; KIDNEY PROXIMAL TUBULE; MALE; MDCK CELL LINE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CHILD; CYTOSINE; DOGS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY TUBULES, PROXIMAL; MADIN DARBY CANINE KIDNEY CELLS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANOPHOSPHONATES; YOUNG ADULT;

EID: 84995739996     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000353     Document Type: Article

References (30)

1. Cihlar T, Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999;56:570-580.
2. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20:641-648.
3. Ho ES, Lin DC, Mendel DB, et al. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000;11:383-393.
4. Gilead. Vistide (cidofovir injection) prescribing information. Available at: http://www. gilead. com/;/media/files/pdfs/medicines/other/vistide/ vistide. pdf. Accessed August 19, 2015.
5. Lacy SA, Hitchcock MJ, Lee WA, et al. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci. 1998;44:97-106.
6. Sweet DH. Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol. 2005;204:198-215.
7. Cundy KC, Li ZH, Lee WA. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab Dispos. 1996;24:315-321.
8. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995;39:882-886.
9. Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections. Viruses. 2010;2:2740-2762.
10. Bidanset DJ, Beadle JR, Wan WB, et al. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis. 2004;190:499-503.
11. Kern ER, Collins DJ, Wan WB, et al. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother. 2004;48:3516-3522.
12. Toth K, Spencer JF, Dhar D, et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A. 2008;105:7293-7297.
13. Buller RM, Owens G, Schriewer J, et al. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology. 2004;318: 474-481.
14. Rice AD, Adams MM, Wallace G, et al. Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011;3: 47-62.
15. Rice AD, Adams MM, Lampert B, et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011;3:63-82.
16. Trost LC, Rose ML, Khouri J, et al. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease. Antivir Res. 2015;117:115-121.
17. Tippin T, Lampert BM, Ware RW, et al. Metabolism and Disposition of 14C-CMX001 in Rats, Monkeys and Humans. 18th North American Regional International Society for the Study of Xenobiotics (ISSX) Meeting; October 14-18, 2012; Dallas, TX. 2012; ISSX Online Abstracts; suppl 7:47.
18. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227-1236.
19. Grimley M, Chemaly R, Englund J, et al. The First Interventional Trial for Adenovirus (AdV): Brincidofovir (CMX001) for AdV in HCT. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO. 2013; Abstract T-351a.
20. Painter W, Robertson A, Trost LC, et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broadspectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012;56:2726-2734.
21. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832-1843.
22. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
23. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Available at: http://www2. kidney. org/professionals/KDOQI/guidelines- ckd/toc. htm. Accessed September 30, 2015.
24. Wright SH, Dantzler WH. Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev. 2004;84:987-1049.
25. Sweet DH, Bush KT, Nigam SK. The organic anion transporter family: from physiology to ontogeny and the clinic. Am J Physiol Ren Physiol. 2001;281:F197-F205.
26. Cihlar T, Laflamme G, Fisher R, et al. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009;53:150-156.
27. Uwai Y, Ida H, Tsuji Y, et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007;24:811-815.
28. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36: 127-143.
29. Cundy KC, Li ZH, Hitchcock MJ, et al. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab Dispos. 1996;24: 738-744.
30. Hsu V, de Vieira LTM, Zhao P, et al. Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet. 2014;53: 283-293.